Search results for " Risk factor"

showing 10 items of 612 documents

Risk factors for hospital readmission of elderly patients

2012

Background: The aim of this study was to identify which factors were associated with a risk of hospital readmission within 3 months after discharge of a sample of elderly patients admitted to internal medicine and geriatric wards. Methods: Of the 1178 patients aged 65 years or more and discharged from one of the 66 wards of the 'Registry Politerapie SIMI (REPOSI)' during 2010, 766 were followed up by phone interview 3 months after discharge and were included in this analysis. Univariate and multivariate logistic regression models were used to evaluate the association of several variables with rehospitalization within 3 months from discharge. Results: Nineteen percent of patients were readmi…

MaleSettore MED/09 - Medicina InternaTime FactorsRisk factors; internal medicine; Geriatric patient; hospital admissionLogistic regressionElderly; Hospital readmission; Internal medicine and geriatric wards; Risk factorsElderlyInternal medicine and geriatric wards80 and overElderly; Hospital readmission; Internal medicine and geriatric wards; Risk factors; Aged; Aged 80 and over; Female; Geriatrics; Hospital Departments; Humans; Internal Medicine; Male; Patient Readmission; Risk Factors; Time Factors; Internal MedicineMedical diagnosisAged Aged; 80 and over Female Geriatrics Hospital Departments Humans Internal Medicine Male Patient Readmission; statistics /&/ numerical data Risk Factors Time FactorsAged 80 and overGeriatricsUnivariate analysisvascular diseaseHospital readmissionSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheAgeing; readmissionstatistics /&/ numerical dataHospital DepartmentFemaleliver diseaseHumanmedicine.medical_specialtyTime FactorHospital DepartmentsMEDLINEHospital readmission Internal medicine and geriatric wards Risk factors Elderlyelderly patientsPatient ReadmissionNOInternal MedicinemedicineHumansRegistry Politerapie SIMI (REPOSI)Adverse effectAgedreadmissionbusiness.industryRisk FactorUnivariatemedicine.diseaseComorbidityHospital readmission; elderly patients; Registry Politerapie SIMI (REPOSI); vascular disease; liver diseaseHospital readmission; Internal medicine and geriatric wards; Risk factors; Elderlyelderly; hospital readmission; risk factors; internal medicine and geriatric wardsInternal medicine and geriatric wardAgeingGeriatric patienthospital admissionRisk factorsGeriatricsEmergency medicinebusinessGeriatricEuropean Journal of Internal Medicine
researchProduct

Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: A comparative risk a…

2014

High blood pressure, blood glucose, serum cholesterol, and BMI are risk factors for cardiovascular diseases and some of these factors also increase the risk of chronic kidney disease and diabetes. We estimated mortality from cardiovascular diseases, chronic kidney disease, and diabetes that was attributable to these four cardiometabolic risk factors for all countries and regions from 1980 to 2010.

MaleSettore MED/09 - Medicina Internakidney diseaseEndocrinology Diabetes and Metabolismhumanoscoste de las enfermedadesDiseaseGlobal HealthCohort StudiesEndocrinologyCost of Illnesscardiovascular diseaseHealth TransitionRisk Factorstransición sanitariaestudios prospectivosRenal Insufficiency Chronic -- complications -- epidemiology -- mortalityevaluación de riesgosRenal InsufficiencyProspective StudiesChronicestudios de cohortesMetabolic Syndromeeducation.field_of_studydiabetesMortality rateAge Factors; Cardiovascular Diseases; Cohort Studies; Cost of Illness; Diabetes Complications; Female; Health Surveys; Humans; Male; Metabolic Syndrome X; Prospective Studies; Renal Insufficiency Chronic; Risk Assessment; Risk Factors; Sex Factors; Spatio-Temporal Analysis; Global Health; Health Transition; Internal Medicine; Endocrinology Diabetes and Metabolism; EndocrinologyMetabolic Syndrome XCardiovascular Diseases -- complications -- epidemiology -- mortalityAge FactorsCardiovascular diseaseDiabetes Mellitus chronic kidney diseaseDiabetes Complications -- epidemiology -- mortalitySciences bio-médicales et agricolesDiabetes and MetabolismCardiovascular Diseasesencuestas de saludFemaleanálisis temporoespacialRisk assessmentcomplicaciones de la diabetesinsuficiencia renalmedicine.medical_specialtyCardiovascular disease; kidney disease; diabetes mortalityPopulationenfermedades cardiovascularesMetabolic Syndrome X -- complications -- epidemiology -- mortalityRisk AssessmentArticleDiabetes ComplicationsSex FactorsSpatio-Temporal Analysiscardiovascular disease; chronic kidney disease; diabetes; mortalityInternal medicineEnvironmental healthDiabetes mellitusmedicineAge Factors; Cardiovascular Diseases; Cohort Studies; Cost of Illness; Diabetes Complications; Female; Health Surveys; Humans; Male; Metabolic Syndrome X; Prospective Studies; Renal Insufficiency Chronic; Risk Assessment; Risk Factors; Sex Factors; Spatio-Temporal Analysis; Global Health; Health Transition; Endocrinology Diabetes and Metabolism; Internal Medicine; EndocrinologyInternal Medicinefactores de riesgoHumansRisk factorRenal Insufficiency Chroniceducationbusiness.industrydiabetes mortalitymedicine.diseasemortalityHealth SurveysEndocrinologyRelative riskAge Factors; Cardiovascular Diseases/complications; Cardiovascular Diseases/epidemiology; Cardiovascular Diseases/mortality; Cohort Studies; Cost of Illness; Diabetes Complications/epidemiology; Diabetes Complications/mortality; Female; Global Health; Health Surveys; Health Transition; Humans; Male; Metabolic Syndrome X/complications; Metabolic Syndrome X/epidemiology; Metabolic Syndrome X/mortality; Prospective Studies; Renal Insufficiency Chronic/complications; Renal Insufficiency Chronic/epidemiology; Renal Insufficiency Chronic/mortality; Risk Assessment; Risk Factors; Sex Factors; Spatio-Temporal Analysisbusinesschronic kidney diseaseKidney diseaseThe Lancet Diabetes and Endocrinology
researchProduct

Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA‐DR and DQ allele frequency

2007

OBJECTIVE: To investigate the relationship of the polymorphic enhancer HS1,2 central to the 3' enhancer complex regulatory region (IgH3'EC) of the immunoglobulin heavy chain genes with systemic sclerosis (SSc) disease and compare it with HLA-DR and DQ associations. METHODS: A total of 116 patients with SSc were classified as diffuse (dSSc) or limited (lSSc), and as carriers of antitopoisomerase I (anti-Scl70) or anticentromere (ACA) antibodies. Allele and genotype frequencies were assessed in the population as a whole and in the two major subsets, dSSc and lSSc. The concentration of peripheral blood immunoglobulin levels was also determined and analysed according to the genotypes. RESULTS: …

MaleSettore MED/16 - REUMATOLOGIAsystemic sclerosisclinical evaluationgenotype phenotype correlationHLA DR antigenSclerodermaGene FrequencyGenotypeImmunology and Allergycentromere antibody; HLA DR antigen; immunoglobulin enhancer binding protein; scl 70 antibody; adult; aged; article; clinical evaluation; controlled study; DNA polymorphism; female; gene frequency; genotype phenotype correlation; human; major clinical study; male; priority journal; risk factor; systemic sclerosis; Adult; Aged; Autoantibodies; Enhancer Elements (Genetics); Esophagus; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; HLA-DQ Antigens; HLA-DR Antigens; Humans; Immunoglobulin Heavy Chains; Male; Middle Aged; Phenotype; Polymorphism Genetic; Scleroderma Systemic; Statistics Nonparametric; Stomacheducation.field_of_studycentromere antibodyStatisticsStomacharticleMiddle AgedExtended Reportimmunoglobulin enhancer binding proteinEnhancer Elements GeneticPhenotypepriority journalrisk factorFemaleImmunoglobulin Heavy ChainsAdultGenotypeImmunologyPopulationBiologyGeneral Biochemistry Genetics and Molecular BiologyStatistics NonparametricEsophagusGeneticRheumatologyHLA-DQ AntigensHLA-DRHumanscontrolled studyEnhancer Elements (Genetics)NonparametricGenetic Predisposition to DiseasehumanPolymorphismAlleleeducationEnhancerAllele frequencyAgedAutoantibodiesscl 70 antibodyPolymorphism GeneticScleroderma SystemicSystemicHLA-DR Antigensmajor clinical studyGenotype frequencySettore BIO/18 - GeneticaDNA polymorphismImmunologyImmunoglobulin heavy chain
researchProduct

Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People

2016

Aims: The objective of this study was to evaluate the prevalence of the prescription of QT-prolonging drugs at hospital admission and discharge and the risk factors associated with their use in older people (aged 65 years and older). Methods: Data were obtained from the REPOSI (REgistro POliterapie SIMI [Società Italiana di Medicina Interna]) registry, which enrolled 4035 patients in 2008 (n = 1332), 2010 (n = 1380), and 2012 (n = 1323). Multivariable logistic regression was performed to determine the risk factors independently associated with QT-prolonging drug use. QT-prolonging drugs were classified by the risk of Torsades de Pointes (TdP) (definite, possible, or conditional) acc…

MaleTORSADES-DE-POINTES INTERVAL PROLONGATION PATIENT CIPROFLOXACIN COHORT DEATH MULTIMORBIDITY AMIODARONE MORTALITY AIFA.Amiodarone030204 cardiovascular system & hematologyCIPROFLOXACINLogistic regressionAmiodaroneElectrocardiography0302 clinical medicineRisk FactorsTorsades de PointesAtrial Fibrillation80 and overPrevalencePharmacology (medical)030212 general & internal medicineAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalizationmedia_commonAged 80 and overTorsades de PointeAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalization; Pharmacology (medical); Geriatrics and Gerontology; Medicine (all)Medicine (all)DEATHMiddle AgedPatient DischargeHospitalizationLong QT SyndromeCohortHospitalized Older PeopleFemalemedicine.drugHumanDrugmedicine.medical_specialtymedia_common.quotation_subjectMULTIMORBIDITYTorsades de pointesPATIENT03 medical and health sciencesPharmacotherapyInternal medicineINTERVAL PROLONGATIONmedicineHumansTORSADES-DE-POINTESCOHORTMedical prescriptionAIFAAgedbusiness.industryMORTALITYRisk FactorSettore MED/09 - MEDICINA INTERNAOdds ratiomedicine.diseaseQT-Prolonging DrugAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalization; Geriatrics and Gerontology; Pharmacology (medical)Physical therapyGeriatrics and Gerontologybusiness
researchProduct

Progression From Paroxysmal to Persistent Atrial Fibrillation. Clinical Correlates and Prognosis

2010

Objectives: We investigated clinical correlates of atrial fibrillation (AF) progression and evaluated the prognosis of patients demonstrating AF progression in a large population. Background: Progression of paroxysmal AF to more sustained forms is frequently seen. However, not all patients will progress to persistent AF. Methods: We included 1,219 patients with paroxysmal AF who participated in the Euro Heart Survey on AF and had a known rhythm status at follow-up. Patients who experienced AF progression after 1 year of follow-up were identified. Results: Progression of AF occurred in 178 (15%) patients. Multivariate analysis showed that heart failure, age, previous transient ischemic attac…

MaleTime FactorPrognosiRisk FactorpredictionMiddle AgedRisk AssessmentSeverity of Illness IndexAtrial FibrillationDisease ProgressionepidemiologyFemaleatrial fibrillation; epidemiology; prediction; prognosis; progression; Aged; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Prognosis; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Disease ProgressionprogressionAgedHuman
researchProduct

Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes

2021

Background and aims: Beyond type 2 diabetes, even a condition of prediabetes is associated with an increased cardiovascular (CV) risk, and HCV infection coexistence represents an exacerbating factor. CV prognosis improvement in prediabetes represents a challenge, due to the increasing prevalence of this metabolic condition worldwide. Hence, we aimed to prospectively assess how direct acting antivirals (DAAs) could affect major cardiovascular events (MACE) in a prediabetic HCV positive cohort. Methods and results: In this prospective multicenter study, we enrolled HCV patients with overt prediabetes. We compared a subgroup of patients treated with DAAs with untreated prediabetic controls. We…

MaleTime FactorsEndocrinology Diabetes and MetabolismCardiovascular risk Direct acting antiviralsHepatitis C virusPrediabetes Aged Antiviral Agents Cardiovascular Diseases FemaleHeart Disease Risk Factors Hepatitis C Humans Incidence Italy Longitudinal Studies Male Middle Aged Prediabetic State Prospective Studies Protective Factors Retrospective Studies Risk AssessmentTime Factors Treatment Outcome Viral LoadMedicine (miscellaneous)Type 2 diabetes030204 cardiovascular system & hematologymedicine.disease_causeDIRECT ACTING ANTIVIRALSLiver disease0302 clinical medicineLongitudinal StudiesProspective StudiesPrediabeteseducation.field_of_studyNutrition and DieteticsIncidenceMiddle AgedViral LoadHepatitis CTreatment OutcomeItalyCardiovascular DiseasesCohortFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyHepatitis C virusPopulation030209 endocrinology & metabolismAntiviral AgentsRisk AssessmentPrediabetic State03 medical and health sciencesInternal medicinemedicineHumanseducationAgedRetrospective Studiesbusiness.industryProtective FactorsCardiovascular riskmedicine.diseaseHeart Disease Risk FactorsDirect acting antiviralHepatitis C virubusinessPrediabetesMace
researchProduct

Sex differences in food choices, adherence to dietary recommendations and plasma lipid profile in type 2 diabetes - The TOSCA.IT study

2016

Background and aims: Diabetic women have a more adverse plasma lipid profile than men. Sex differences in dietary habits may play a role, but are little investigated. The study evaluates the quality of diet, adherence to the nutritional recommendations of the Diabetes and Nutrition Study Group and their relation with plasma lipid in men and women with diabetes. Methods and results: We studied 2573 people, aged 50e75, enrolled in the TOSCA.IT study (clinicaltrials.gov; NCT00700856). Plasma lipids were measured centrally. Diet was assessed with a semi-quantitative food frequency questionnaire.Women had a more adverse plasma lipid profile than men.Women consumed significantly more legumes, veg…

MaleTime FactorsHealthy DietEndocrinology Diabetes and MetabolismSaturated fatMedicine (miscellaneous)Type 2 diabetesCardiovascular risk factors; Diabetes; Dietary habits; Men; Nutritional recommendations; Sex differences; Women; Medicine (miscellaneous); Nutrition and Dietetics; Endocrinology Diabetes and Metabolism; Cardiology and Cardiovascular MedicineDiabeteRecommended Dietary AllowancesChoice Behaviorchemistry.chemical_compound0302 clinical medicineEndocrinologyRisk FactorsCardiovascular risk factors; Diabetes; Dietary habits; Men; Nutritional recommendations; Sex differences; Women; Aged; Biomarkers; Diabetes Mellitus Type 2; Female; Food Preferences; Humans; Italy; Lipids; Male; Middle Aged; Nutrition Assessment; Risk Factors; Sex Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Choice Behavior; Feeding Behavior; Healthy Diet; Patient Compliance; Recommended Dietary Allowances; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular MedicineSurveys and QuestionnairesFood choiceMedicine030212 general & internal medicineFood scienceCardiovascular risk factorsNutrition and DieteticsDietary habitsDiabetesMenMiddle AgedLipidsDiabetes and MetabolismTreatment OutcomeItalySaturated fatty acidFemaleDiet HealthyCardiology and Cardiovascular MedicineType 2030209 endocrinology & metabolismAdded sugarDietary habit03 medical and health sciencesFood PreferencesSex FactorsDiabetes mellitusSex differencesDiabetes MellitusHumansWomenAgedCardiovascular risk factors; Diabetes; Dietary habits; Men; Nutritional recommendations; Sex differences; Women; Aged; Biomarkers; Diabetes Mellitus Type 2; Female; Food Preferences; Humans; Italy; Lipids; Male; Middle Aged; Nutrition Assessment; Risk Factors; Sex Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Choice Behavior; Diet Healthy; Feeding Behavior; Patient Compliance; Recommended Dietary AllowancesHealthybusiness.industryUnsaturated fatNutritional recommendationFeeding BehaviorSex differencemedicine.diseaseDietNutrition AssessmentchemistryDiabetes Mellitus Type 2Patient ComplianceNutritional recommendationsGlycated hemoglobinbusinessBiomarkers
researchProduct

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

2016

International audience; BACKGROUND:We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC).METHODS:In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overal…

MaleTime FactorsIntention to Treat Analysimedicine.medical_treatmentMedizinPROGRESSIONKaplan-Meier EstimateLiver transplantationGastroenterologyImmunosuppressive Agent0302 clinical medicineEVEROLIMUSRENAL-CELL CARCINOMARisk FactorsMedicine and Health SciencesClinical endpointAge FactorSirolimuProspective StudiesIMMUNOSUPPRESSIONTOR Serine-Threonine KinaseTOR Serine-Threonine KinasesHazard ratioLiver NeoplasmsAge FactorsImmunosuppressionMiddle AgedCANCER3. Good healthIntention to Treat AnalysisEuropeRAPAMYCIN INHIBITORSTreatment OutcomeTARGETLocalLiver Neoplasm030220 oncology & carcinogenesisCombinationDisease ProgressionSURVIVAL[SDV.IMM]Life Sciences [q-bio]/Immunology030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugHumanAdultmedicine.medical_specialtyCanadaCarcinoma HepatocellularTime Factor[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryRisk AssessmentDisease-Free Survival03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansAdult; Age Factors; Aged; Australia; Canada; Carcinoma Hepatocellular; Disease Progression; Disease-Free Survival; Drug Therapy Combination; Europe; Female; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Prospective Studies; Risk Assessment; Risk Factors; Sirolimus; TOR Serine-Threonine Kinases; Time Factors; Treatment Outcome; Young Adult; Liver Transplantation; TransplantationRECURRENCEMETAANALYSISAgedSirolimusTransplantationEverolimusIntention-to-treat analysisbusiness.industryRisk FactorCarcinomaAustraliaHepatocellular3126 Surgery anesthesiology intensive care radiologySurgeryLiver TransplantationTransplantationProspective StudieNeoplasm RecurrenceSirolimusNeoplasm Recurrence Localbusiness
researchProduct

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

2009

International audience; BACKGROUND: Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a prospective observational cohort study. METHODS: 19,486 patients with inflammatory bowel disease, of whom 11,759 (60.3%) had Crohn's disease and 7727 (39.7%) had ulcerative colitis or unclassified inflammatory bowel disease, were enrolled in a nationwide French cohort by 680 gastroenterologists, who reported details of immunosuppressive therapy during the observation period, cases of cancer, and deaths. The risk of lymphoproliferative disorder was assessed according to thiopurine expos…

MaleTime FactorsMESH : Age DistributionMESH : Prospective StudiesMESH : AgedInflammatory bowel diseaseMESH: Proportional Hazards Models0302 clinical medicineMESH: Lymphoproliferative DisordersCrohn DiseaseRisk FactorsMESH: Risk FactorsMESH : PurinesMESH : FemaleProspective StudiesMESH: IncidenceProspective cohort studyMESH : Immunosuppressive AgentsMESH : Sex DistributionMESH: AgedMESH : Tumor Necrosis Factor-alphaCrohn's diseaseMESH: Middle AgedThiopurine methyltransferasebiologyMESH : Lymphoproliferative DisordersIncidenceMESH: Sex DistributionGeneral MedicineMESH: PurinesMiddle AgedMESH : AdultMESH : Colitis UlcerativeUlcerative colitisMESH : Risk FactorsMESH : Incidence3. Good health030220 oncology & carcinogenesisCohortDrug Therapy CombinationFemale030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFranceMESH: Immunosuppressive AgentsImmunosuppressive AgentsCohort studyMESH : Time FactorsAdultmedicine.medical_specialtyMESH : MaleMESH: Colitis UlcerativeLymphoproliferative disordersMESH : Crohn DiseaseMESH: Multivariate Analysis03 medical and health sciencesAge DistributionInternal medicinemedicineHumansMESH : Middle AgedSex DistributionMESH : FranceMESH: Age DistributionAgedProportional Hazards ModelsMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphabusiness.industryMESH : Drug Therapy CombinationMESH: Time FactorsMESH : HumansMESH : Multivariate AnalysisMESH: Adult[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseMESH : Proportional Hazards ModelsLymphoproliferative DisordersMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceMESH: Drug Therapy CombinationPurinesMESH: Tumor Necrosis Factor-alphaMultivariate Analysisbiology.proteinColitis UlcerativebusinessMESH: Female
researchProduct

Incremental predictive value of mean platelet volume/platelet count ratio in in-hospital stroke after acute myocardial infarction.

2017

IF 2.558; International audience; Stroke is a serious complication after acute myocardial infarction (AMI) and is associated with an increased risk of death. Though the pathophysiological mechanisms are not exactly known, increased inflammation and platelet reactivity could play an important role in the occurrence of stroke during AMI. We aimed to investigate the relationship between both mean platelet volume (MPV), a parameter of platelet function, and C-reactive protein (CRP) and the occurrence of in-hospital ischemic stroke (IHS) after AMI. Data were obtained from a French regional survey for AMI that included 5976 patients admitted to an intensive care unit (ICU) between 2001 and 2010. …

MaleTime FactorsMESH : StrokeMyocardial InfarctionMESH : AgedMESH: ComorbidityComorbidityMESH: Hospitalization030204 cardiovascular system & hematologyMESH : Platelet Countlaw.inventionMESH: Proportional Hazards Models0302 clinical medicineMESH: Aged 80 and overRisk FactorslawMESH: Risk FactorsOdds Ratio[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleMyocardial infarctionMESH : BiomarkersStrokeMESH: Blood PlateletsAged 80 and overMESH: AgedEjection fractionMESH: Middle AgedMESH : PrognosisbiologyMESH : Mean Platelet Volume[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyGeneral MedicineMiddle AgedPrognosisIntensive care unitstrokeMESH : Risk Factors3. Good healthHospitalizationMESH: Myocardial Infarctionrisk factorplateletsMESH : ComorbidityCardiologyMESH : HospitalizationFemaleMean Platelet VolumeMESH : Time FactorsBlood Plateletsmedicine.medical_specialtyMESH : Male[SDV.BC]Life Sciences [q-bio]/Cellular BiologyAcute myocardial infarctionMESH: PrognosisMESH: StrokeC-reactive protein03 medical and health sciencesInternal medicinemedicineHumansMESH : Middle AgedMESH: Platelet Countcardiovascular diseasesRisk factorMean platelet volumeMESH : Aged 80 and overSurvival analysisAgedProportional Hazards ModelsMESH: HumansPlatelet Countbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyC-reactive proteinMESH: Time FactorsMESH : HumansMESH : Blood Plateletsmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Odds RatioMESH: MaleMESH: Mean Platelet Volumebiology.proteinMESH: BiomarkersMESH : Odds RatioMESH : Myocardial InfarctionbusinessMESH: FemaleBiomarkers030217 neurology & neurosurgery
researchProduct